Want to see KR:000070 full AI Analyst Report?
Samyang Holdings Corporation (000070) Price & Analysis
000070 Stock Chart & Stats
- Day’s Range
- KRW 51,400.00 - KRW 52,300.00
- 52-Week Range
- KRW 51,400.00 - KRW 118,483.56
- Previous Close
- KRW 52,500.00
- Volume
- N/A
- Average Volume (3M)
- 6,807
- Market Cap
- KRW 361.62B
- Enterprise Value
- KRW 2.34T
- Total Cash (Recent Filing)
- KRW 790.37B
- Total Debt (Recent Filing)
- KRW 1.90T
- Price to Earnings (P/E)
- ―
- Beta
- 0.32
- Next Earnings
- Nov 18, 2026
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 6.69%
Bulls Say, Bears Say
Bulls Say
Positive Free Cash Flow
Positive operating and free cash flow through the TTM period, including roughly KRW 127B of TTM FCF, provides internal liquidity for obligations and selective investment. This cushion is valuable while earnings are weak, although durability depends on restoring profitability.
Stable Gross Margin
Relatively stable TTM revenue and a gross margin holding near 16–18% indicate that the operating portfolio retains some underlying commercial resilience. Preserving gross profitability can support recovery efforts and provide a base for earnings improvement if cost pressures ease.
Access To Debt Markets
The enlarged bond offering and AA- ratings from two Korean agencies demonstrate continued access to institutional financing. Using proceeds primarily for debt repayment reflects balance-sheet discipline and could improve refinancing flexibility, even though the issuance also adds near-term obligations.
Bears Say
Sustained Net Losses
The shift from profits in 2022–2024 to sizable losses in 2025 and the TTM period is the most significant fundamental weakness. A negative net margin reduces retained capital, limits flexibility for investment or distributions, and signals that current operations are not converting revenue into shareholder returns.
Rising Leverage
Debt-to-equity has risen materially from prior-year levels to about 1.02 while returns on equity remain negative. Higher leverage increases fixed financial commitments and reduces room to absorb prolonged losses, potentially constraining capital allocation across the holding-company portfolio.
Thin Operating Profitability
A TTM operating margin of only about 4.1% leaves limited protection against cost increases or business volatility. Combined with negative TTM free-cash-flow growth and a prior negative FCF year, this suggests cash generation may not remain dependable if weak profitability persists.
Samyang Holdings Corporation News
000070 FAQ
What was Samyang Holdings Corporation’s price range in the past 12 months?
What is Samyang Holdings Corporation’s market cap?
When is Samyang Holdings Corporation’s upcoming earnings report date?
How were Samyang Holdings Corporation’s earnings last quarter?
Is Samyang Holdings Corporation overvalued?
Does Samyang Holdings Corporation pay dividends?
What is Samyang Holdings Corporation’s EPS estimate?
How many shares outstanding does Samyang Holdings Corporation have?
What happened to Samyang Holdings Corporation’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Samyang Holdings Corporation?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Samyang Holdings Corporation
Samyang Holdings Corporation, a diversified conglomerate founded in Seoul, South Korea, in 1924, engages in a wide array of activities through its various subsidiaries. The company's operations span the chemical, food, packaging, pharmaceutical, and IT service sectors. Its chemical division manufactures an extensive range of advanced materials, including value-added chemicals, terephthalic acid, various polycarbonate (PC) resins, bisphenol-A, and specialized engineering plastics. They also produce PC and polybutylene terephthalate compounds, PET bottles, and long fiber reinforced thermoplastics. In the food business, Samyang offers both health and wellness products and starch-based sugars. The company also extends into consumer services, operating the Seven Springs salad and brunch restaurant concept, along with Café Seven Springs bakeries. Its pharmaceutical arm develops and markets anti-cancer treatments such as Genexol and Nanoxel PM, in addition to medical devices like the NicoStop smoking cessation patch and biodegradable surgical sutures, including Trisorb and Monosorb. Samyang's products have a global reach, being exported to over 80 countries. Furthermore, Samyang provides comprehensive IT services, offering consulting for system management and integration, e-business solutions, and enterprise software (ERP, e-HR, MES, and mobile services) to clients in the public, finance, and manufacturing industries.
- Sector
- General
- Industry
- Conglomerates
- CEO
- Tae-Ung Eom
- Employees
- 145
- Website
- www.samyang.com
- Address
- 31 Jongno 33-gil, Seoul, SL, 03129, KR
Samyang Holdings Corporation (000070) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 3 | 13 |
| Technical Analysis | 4 | 3 | 2 |
| Moving Averages | 1 | 0 | 11 |

